Sobi to Showcase Scientific advances and Commitment to the Haemophilia community at EAHAD 2026

Sobi (STO:SOBI) will present seven haemophilia abstracts at EAHAD 2026, highlighted by an oral presentation of three-year XTEND-ed extension data for ALTUVOCT (efanesoctocog alfa) showing continued prophylactic protection, few bleeds and no unexpected safety issues. The clinical readouts support the product’s long-term profile and reinforce Sobi’s commercial position in territories where it holds rights under its collaboration with Sanofi; Sobi reported SEK 26 billion revenue in 2024. While encouraging for medium-term adoption and market positioning in haemophilia A, the updates are incremental clinical data rather than an immediate regulatory or earnings shock.

Analysis

Market structure: Positive three‑year XTEND‑ed data strengthens Sobi’s (STO:SOBI) commercial proposition in Europe/North Africa/Middle East and indirectly supports Sanofi (SNY) in North America by de‑risking global launch sequencing. Expect modest share gains vs incumbent FVIII prophylaxis products and pricing resilience in premium segments, but penetration will be gradual—realistic uptake of 5–15% of severe HA prophylaxis patients in target markets over 2–3 years rather than immediate blockbuster substitution.

Risk assessment: Near‑term event risk centers on EAHAD presentation (6 Feb 2026) and potential market reaction; tail risks include unforeseen safety/regulatory setbacks (EMA/CHMP inquiries), manufacturing interruptions, or rapid competitive gene‑therapy adoption. Time buckets: immediate (±10 trading days around 6 Feb), short (3–12 months for formulary/reimbursement movement), long (2–5 years for market share vs gene therapy). Hidden dependency: Sobi’s economics are capped by the Sobi/Sanofi territory split—European upside doesn’t fully translate to Sanofi and vice versa.

Trade implications: Event‑driven, asymmetric opportunities exist—buy Sobi exposure ahead of the EAHAD oral presentation (limited-capital options or stock with tight stops) and hedge commercialization uncertainty via short exposure to high‑valuation hemophilia developers (e.g., BMRN) over 6–12 months. Volatility will compress after the presentation (IV crush); prefer directional spread structures to limit premium loss. Monitor SEK funding and Sobi CDS for credit signals.

Contrarian angle: Consensus may overestimate immediate sales translation from positive extension data; payers will demand health‑economic evidence and tend to delay adoption—this implies the market could be overpricing short‑term upside for SOBI/SNY. Conversely, if Altuvoct demonstrates durable bleed reduction with favorable joint‑health endpoints, upside could be underappreciated—prepare asymmetric bets sized to these binary outcomes.

Key Decisions for Investors

• Establish a 2–3% long position in SOBI (STO:SOBI) equities 5–10 trading days before 6 Feb 2026 and trim/close within 3 trading days after the oral presentation; set a 6–8% stop‑loss and target 12–18% upside on positive readthrough to sales guidance.
• Deploy a tactical 1–2% portfolio long via a 3‑month call spread on SNY (Sanofi) to capture North American commercialization optionality—buy near‑ATM calls and sell 10–15% OTM calls to cap premium, exit within 60–90 days if uptake signals are weak.
• Enter a 0.5–1.0% pair trade: long SOBI vs short BioMarin (BMRN) equal dollar notional to hedge gene‑therapy tail risk; hold 6–12 months and rebalance if reimbursement or pivotal regulatory news occurs.
• Avoid naked long options on SOBI through the presentation due to expected IV crush; if seeking volatility, buy an ATM call spread expiring 1–2 weeks after 6 Feb to limit premium decay (size 0.5–1% of portfolio).
• Monitor four KPIs within 30–90 days (EAHAD slides/details, European reimbursement decisions, real‑world bleeding rate reductions >20% vs standards, any EMA safety queries); reduce exposure by half if any one KPI misses materially.